Article
Favipiravir-resistant influenza A virus shows potential for transmission
2020-09-01
Abstract excerpt
Favipiravir is a nucleoside analogue which has been licensed to treat influenza in the event of a new pandemic. We previously described a favipiravir resistant influenza A virus generated by in vitro passage in presence of drug with two mutations: K229R in PB1, which conferred resistance at a cost to polymerase activity, and P653L in PA, which compensated for the cost of polymerase activity. However, the clinical...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ed0bb6a3-304d-5fb1-9b1d-5557da2fbf3a
- DOI
- 10.1101/2020.09.01.277343
